Who are Intra-Arterial TNK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): low-dose tenecteplase intravenous thrombolysis, Fibrinolytic twice daily, Fibrinolytic once daily, Fibrinolytic therapy, rhPro-UK simulation agent, Intravenous Tenecteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intra-arterial-tnk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intra-Arterial TNK — Competitive Intelligence Brief

Intra-Arterial TNK (Intra-Arterial TNK) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular / Neurology.

phase 3 Fibrinolytic agent / Thrombolytic Plasminogen / Fibrin Cardiovascular / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Intra-Arterial TNK (Intra-Arterial TNK) — Tianjin Huanhu Hospital. TNK (tenecteplase) is a fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin when administered directly into an artery.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intra-Arterial TNK TARGET	Intra-Arterial TNK	Tianjin Huanhu Hospital	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic twice daily	Fibrinolytic twice daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent	Plasminogen / Fibrin
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Fibrinolytic therapy	Fibrinolytic therapy	All India Institute of Medical Sciences	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
rhPro-UK simulation agent	rhPro-UK simulation agent	Tasly Biopharmaceuticals Co., Ltd.	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Intravenous Tenecteplase	Intravenous Tenecteplase	NHS Greater Glasgow and Clyde	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

All India Institute of Medical Sciences · 1 drug in this class
Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Beijing Chao Yang Hospital · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Life Recovery Systems · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Thrombolex, Inc. · 1 drug in this class
Tianjin Huanhu Hospital · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intra-Arterial TNK — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-arterial-tnk. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab